{
  "report_rows": [
    {
      "kpi": "Net sales",
      "prediction": "BEAT",
      "answer": "pred ~$1.06B vs. cons $1.03B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA",
      "prediction": "BEAT",
      "answer": "pred ~$465M vs. cons $450M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.78 vs. cons $2.67",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 net-sales guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.05B vs. cons $5.06B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted-EBITDA guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.70B vs. cons $2.71B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Section 45X-credit assumption",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.15B vs. cons $2.15B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 5.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "FADE",
  "day5_rationale": "A ~$465M EBITDA result versus ~$450M consensus and a ~$2.70B FY2026 EBITDA midpoint versus ~$2.71B consensus should initially reward a clean execution print, but unchanged guidance leaves limited out-period estimate upside and preserves Section 232, project-timing, and 2027 normalization uncertainty.",
  "day5_confidence": "MEDIUM"
}